Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beta-blockers in Spinal Hemangioma
NCT05106179Phase 4Unknown
- Sponsor
- CVPath Institute
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of atenolol and propranolol in spinal hemangioma (2 arms), sponsored by CVPath Institute. Primary endpoints: Reducing tumor growth at 3 months, Reducing tumor at 6 months and 1 more. Status: unknown.
02
Drugs
atenololpropranolol
03
Conditions
spinal hemangioma
Beyond the preview
Go deeper on NCT05106179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05106179.